Paion – executive interview

>> DOWNLOAD LINK 🎞️ #1 <<

>> DOWNLOAD LINK 🎞️ #2 <<

>> COPY / PASTE LINK PLEASE 🎵 MP3 <<

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=9tybmD_YeKg

Paion has gained approvals in the US, China and Japan for its fast-onset, short-recovery anaesthesia product remimazolam. In the US, partner Acacia is expected to launch it in Q420 for procedural sedation (PS). In Japan, Mundipharma launched it in Q320 for general anaesthesia (GA). In China, Yichang Humanwell launched it for PS in August, with GA trials ongoing. Initial European PS approval is expected by H121. European marketing will be either direct or using regional partners. Paion indicates it has cash until H221. • See more at: https://www.edisongroup.com/edison-tv/

#############################